Following positive phase 2 results from its ready-to-use liquid formulation botulinum toxin, global pharmaceutical company Galderma has received a manufacturing license from the Swedish Medical Products Agency (MPA) for a new state-of-the-art manufacturing facility at the Center of Excellence, located in Uppsala, Sweden.
Global pharmaceutical company Galderma’s liquid formulation of botulinum toxin type A has achieved positive results for the treatment of glabellar lines in a phase 2 clinical trial.
We bring you the most up-to-date information for the Aesthetics community across a variety of media, including; news, webinars, podcasts, the Journal, reports, interviews and more!
aesthetics Journal
The Aesthetics Journal is the leading monthly publication for the medical aesthetics specialty. It is peer reviewed and spans an incredible volume of topics. Become a member today to receive the monthly print and digital Journal.
0203 096 1228
2nd Floor, Regal House, 70 London Road
Twickenham TW1 3QS, United Kingdom
© 2023 Easyfairs UK Ltd | Registered in England No. 05067979
